Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption

Ascendis Pharma A/S (ASND) is down 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks driven more by capital-structure and trading-mechanics factors than a new clinical headline. Investors have been digesting Ascendis’ switch from ADSs to directly listed ordinary shares and a newly announced call/redemption of its 2028 convertible notes, both of which can spark hedging, arbitrage unwinds, and dilution concerns.

Details:

Ascendis announced it will redeem all $575 million principal amount of its 2.25% convertible senior notes due 2028, with a May 6, 2026 redemption date, and noteholders can convert prior to the deadline.

The company disclosed that up to roughly 3.6 million ordinary shares could be issuable if the notes are converted during the “make-whole” conversion period tied to the redemption notice, raising near-term dilution/flow questions.

Ascendis recently transitioned its Nasdaq listing from ADSs to directly listed ordinary shares under the same ticker, a change that can temporarily disrupt liquidity and prompt position rebalancing.

Separately, Ascendis reported the closing of a warrant exercise window and an increase in share capital, which may have added incremental selling pressure around the transition.

Sources:

Ascendis Pharma (Investor Relations), SEC (Form 6-K), Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ASND Hedge Fund Activity

We have seen 177 institutional investors add shares of $ASND stock to their portfolio, and 125 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,586,394 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $338,282,656
AMERICAN CENTURY COMPANIES INC added 898,535 shares (+165.0%) to their portfolio in Q4 2025, for an estimated $191,603,603
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 494,995 shares (-13.3%) from their portfolio in Q4 2025, for an estimated $105,552,733
CITADEL ADVISORS LLC added 491,876 shares (+1779.6%) to their portfolio in Q4 2025, for an estimated $104,887,638
POLAR CAPITAL HOLDINGS PLC removed 487,438 shares (-56.8%) from their portfolio in Q4 2025, for an estimated $103,941,279
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 470,951 shares (+inf%) to their portfolio in Q4 2025, for an estimated $100,425,591
VESTAL POINT CAPITAL, LP removed 425,000 shares (-70.8%) from their portfolio in Q4 2025, for an estimated $90,627,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ASND Analyst Ratings

Wall Street analysts have issued reports on $ASND in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/30/2026
Stifel issued a "Buy" rating on 12/11/2025
Wedbush issued a "Outperform" rating on 11/18/2025

To track analyst ratings and price targets for $ASND, check out Quiver Quantitative's $ASND forecast page.

$ASND Price Targets

Multiple analysts have issued price targets for $ASND recently. We have seen 9 analysts offer price targets for $ASND in the last 6 months, with a median target of $290.0.

Here are some recent targets:

Tazeen Ahmad from B of A Securities set a target price of $292.0 on 04/16/2026
Yun Zhong from Wedbush set a target price of $273.0 on 04/09/2026
Kelly Shi from Jefferies set a target price of $290.0 on 03/16/2026
Luca Issi from RBC Capital set a target price of $275.0 on 03/03/2026
Leland Gershell from Oppenheimer set a target price of $262.0 on 02/12/2026
Eliana Merle from Barclays set a target price of $342.0 on 01/28/2026
Derek Archila from Wells Fargo set a target price of $330.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.